Kovio was founded on the belief that innovation alone is insufficient to sustain growth in regulated industries. Durable growth requires structured execution architecture that aligns regulatory readiness, commercial scale, and AI governance.
We partner with leadership teams and investors to embed execution discipline and scalable operating systems.
Kovio was founded by an executive with more than two decades of experience spanning medical device product development at GE and a decade of pharmaceutical R&D, drug development, and regulatory compliance leadership.
His career bridges two of the most demanding disciplines in regulated industries — the engineering rigor and systems thinking of medical device development, and the scientific and regulatory complexity of pharmaceutical product development. This rare combination informs Kovio's core belief: that durable growth in regulated industries requires structured execution architecture, not just subject matter expertise.
His pharmaceutical experience spans drug development, modeling and simulation, commercial strategy, and regulatory compliance — giving him direct insight into the operational and institutional challenges that growth-stage pharma and biotech companies face as they scale.
As a founder and executive operator, he has led cross-functional teams, built regulatory and commercial frameworks, and worked at the intersection of innovation and compliance — the exact terrain where Kovio operates.
Kovio was built on the conviction that the most valuable thing an execution partner can bring is not a framework off a shelf, but hard-won operational experience from inside regulated industries.
Kovio collaborates with experienced regulatory, commercial, and enterprise leaders who provide perspective on execution architecture, regulatory modernization, and institutional operating discipline.
Advisor engagement is structured, focused, and high-leverage.